Key result
Empirical additional ablation will be compared to conventional single point ablation in a planned randomized trial of 315 patients to determine its efficacy in preventing recurrence of outflow tract premature ventricular complexes.
Why the study?
Late recurrence after catheter ablation remains a significant issue in patients with premature ventricular complexes, and whether empirical additional ablation improves long-term control of outflow tract PVCs compared with limited single point ablation is unknown.
Does empirical additional ablation reduce PVC recurrence in patients with outflow tract premature ventricular complexes compared to single point ablation?
RCT (n=315)
Open-label
1:1 central randomization using permuted blocks
Yes
Does empirical additional ablation reduce PVC recurrence in patients with outflow tract premature ventricular complexes compared to single point ablation?
The EASE-PVC trial protocol outlines a randomized comparison to determine if empirical additional ablation improves 3-month freedom from PVC recurrence compared to single-point ablation in patients with outflow tract PVCs.
Empirical additional ablation for outflow tract PVCs should not yet change practice; EASE-PVC trial leaves its efficacy versus single-point ablation open.
BACKGROUND: Late recurrence after ablation remains a significant issue in patients with premature ventricular complexes (PVCs) who undergo catheter ablation. In this study, we aimed to test the hypothesis that empirical additional ablation (EAA) would improve the long-term control of PVCs from outflow tracts (OT-PVCs) compared with the approach of limited single point ablation at the assumptive location. METHODS: EASE-PVC study (ChiCTR2200055340) is a prospective multi-center, randomized, and controlled trial designed to assess the effectiveness and safety of empirical additional ablation in patients with OT-PVCs. After successful elimination of OT-PVCs, the patients will be randomized into two groups. In patients randomized to the EAA group, additional lesion applications at sites surrounding the successful ablation site will be delivered empirically. For patients randomized to the control group, no additional empiric ablation will be performed around the successful ablation site. The primary endpoint will be freedom from PVC recurrence at 3 months following ablation, without antiarrhythmic drug therapy. CONCLUSIONS: The EASE-PVC study is designed to compare the effectiveness and safety of two different strategies for ablation in patients with OT-PVCs, namely empirical additional ablation strategy versus conventional single point ablation strategy. This prospective, multi-center, and randomized controlled trial, with comparative data evaluating procedural and long-term follow-up results, aims to elucidate the superiority of empirical additional ablation for the long-term control of OT-PVCs compared with the traditional single point ablation strategy. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trials Registry Identifier: ChiCTR2200055340.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) conducted an RCT in Premature ventricular complexes from the outflow tract (OT-PVCs) (n=315). Empirical additional ablation (EAA) vs. Conventional single point ablation was evaluated on Freedom from PVC recurrence (≥80% reduction of PVC burden) at 3 months following ablation, without antiarrhythmic drug therapy. Empirical additional ablation will be compared to conventional single point ablation in a planned randomized trial of 315 patients to determine its efficacy in preventing recurrence of outflow tract premature ventricular complexes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: